Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-26T17:47:47.389Z Has data issue: false hasContentIssue false
  • English
  • Français

The Value of Detecting Pathological Changes During Clot Formation in Early Disease Treatment-Naïve Breast Cancer Patients

Published online by Cambridge University Press:  02 February 2021

Julien Paul Nunes Goncalves ,
Greta Marie de Waal ,
Martin Justin Page ,
Chantelle Venter ,
Timothy Roberts ,
Felix Holst ,
Etheresia Pretorius  and
Janette Bester Open the ORCID record for Janette Bester [Opens in a new window]
Julien Paul Nunes Goncalves
Affiliation:
Department of Physiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
Greta Marie de Waal
Affiliation:
Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa
Martin Justin Page
Affiliation:
Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa
Chantelle Venter
Affiliation:
Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa
Timothy Roberts
Affiliation:
Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa Department of Biochemistry, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK University College London Hospital NHS Foundation Trust, 250 Euston Road, LondonNW1 2PB, UK
Felix Holst
Affiliation:
Department of Surgery, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa
Etheresia Pretorius
Affiliation:
Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa
Janette Bester*
Affiliation:
Department of Physiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
*
*Author for correspondence: Janette Bester, E-mail: [email protected]
Get access

Abstract

Breast cancer (BC) is one of the most prevalent forms of cancer in women worldwide. Clinical research indicates that BC patients are at an increased risk for thrombotic events, drastically decreasing their quality-of-life and treatment outcomes. There is ample evidence of this in the literature, but it is mainly focused on metastatic BC. Therefore, coagulopathies of nonmetastatic BC are understudied and require in-depth investigation. In this study, clot kinetics and ultrastructure were used to investigate treatment-naïve, nonmetastatic BC patients using scanning electron microscopy, Thromboelastography®, and confocal laser scanning microscopy. It was demonstrated that nonmetastatic BC patients exhibit minimal ultrastructural alterations of the clot components and no changes in the clot kinetics. However, BC patients presented changes to fibrinogen protein structure, compared to matched controls, using an amyloid-selective stain. Together, these findings suggest that coagulation dysfunction(s) in BC patients with early disease manifest at the microlevel, rather than the macrolevel. This study presents novel insights to a method that are more sensitive to coagulation changes in this specific patient group, emphasizing that the coagulation system may react in different forms to the disease, depending on the progression of the disease itself.

Keywords

breast cancerconfocal microscopynon-metastaticscanning electron microscopythrombosis
Type
Biological Applications
Information
Microscopy and Microanalysis , Volume 27 , Issue 2 , April 2021 , pp. 425 - 436
Check for updates
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press on behalf of the Microscopy Society of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aggarwal, BB, Vijayalekshmi, R & Sung, B (2009). Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. Clin Cancer Res 15, 425–430.CrossRefGoogle ScholarPubMed
Balkwill, F & Mantovani, A (2001). Inflammation and cancer: Back to Virchow? Lancet 357, 539–545.CrossRefGoogle ScholarPubMed
Benson, JR & Jatoi, I (2012). The global breast cancer burden. Future Oncol 8, 697–702.CrossRefGoogle ScholarPubMed
Bester, J, Matshailwe, C & Pretorius, E (2018). Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8. Cytokine 110, 237–242.CrossRefGoogle ScholarPubMed
Bester, J & Pretorius, E (2016). Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep 6, 1–10.CrossRefGoogle ScholarPubMed
Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA & Jemal, A (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394–424.CrossRefGoogle ScholarPubMed
Caine, GJ, Stonelake, PS, Lip, GY & Kehoe, ST (2002). The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia 4, 465.CrossRefGoogle ScholarPubMed
Connolly, GC, Phipps, RP & Francis, CW (2014). Platelets and cancer-associated thrombosis. Semin Oncol 41, 302–310.CrossRefGoogle ScholarPubMed
de Waal, GM, De Villiers, WJS, Forgan, T, Roberts, T & Pretorius, E (2020). Colorectal cancer is associated with increased circulating lipopolysaccharide, inflammation and hypercoagulability. Sci Rep 10, 8777.CrossRefGoogle ScholarPubMed
Elston, CW & Ellis, IO (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19, 403–410.CrossRefGoogle ScholarPubMed
Falanga, A, Russo, L, Milesi, V & Vignoli, A (2017). Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol 118, 79–83.CrossRefGoogle ScholarPubMed
Falanga, A, Russo, L & Verzeroli, C (2013). Mechanisms of thrombosis in cancer. Thromb Res 131, S59–S62.CrossRefGoogle ScholarPubMed
Franco, AT, Corken, A & Ware, J (2015). Platelets at the interface of thrombosis, inflammation, and cancer. Blood 126, 582–588.CrossRefGoogle ScholarPubMed
Hartmann, J, Mason, D & Achneck, H (2018). Thromboelastography (TEG) point-of-care diagnostic for hemostasis management. Point of Care 17, 15–22.CrossRefGoogle Scholar
Key, TJ, Verkasalo, PK & Banks, E (2001). Epidemiology of breast cancer. Lancet Oncol 2, 133–140.CrossRefGoogle ScholarPubMed
Khorana, A, Francis, C, Culakova, E, Kuderer, N & Lyman, G (2007). Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemostasis 5, 632–634.CrossRefGoogle ScholarPubMed
Kravchenko, J, Akushevich, I, Seewaldt, VL, Abernethy, AP & Lyerly, HK (2011). Breast cancer as heterogeneous disease: Contributing factors and carcinogenesis mechanisms. Breast Cancer Res Treat 128, 483–493.CrossRefGoogle ScholarPubMed
Levi, M & Van Der Poll, T (2010). Inflammation and coagulation. Crit Care Med 38, S26–S34.CrossRefGoogle ScholarPubMed
Lima, LG & Monteiro, RQ (2013). Activation of blood coagulation in cancer: Implications for tumour progression. Biosci Rep 33, e00064.CrossRefGoogle ScholarPubMed
Lip, GY, Chin, BS & Blann, AD (2002). Cancer and the prothrombotic state. Lancet Oncol 3, 27–34.CrossRefGoogle ScholarPubMed
Mandalà, M, Ferretti, G, Cremonesi, M, Cazzaniga, M, Curigliano, G & Barni, S (2003). Venous thromboembolism and cancer: New issues for an old topic. Crit Rev Oncol Hematol 48, 65–80.CrossRefGoogle ScholarPubMed
Méndez-García, LA, Nava-Castro, KE, Ochoa-Mercado, TDL, Palacios-Arreola, MI, Ruiz-Manzano, RA, Segovia-Mendoza, M, Solleiro-Villavicencio, H, Cázarez-Martínez, C & Morales-Montor, J (2019). Breast cancer metastasis: Are cytokines important players during Its development and progression? J Interferon Cytokine Res 39, 39–55.CrossRefGoogle ScholarPubMed
Mezouar, S, Frère, C, Darbousset, R, Mege, D, Crescence, L, Dignat-George, F, Panicot-Dubois, L & Dubois, C (2016). Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Thromb Res 139, 65–76.CrossRefGoogle ScholarPubMed
Nicolini, A, Carpi, A & Rossi, G (2006). Cytokines in breast cancer. Cytokine Growth Factor Rev 17, 325–337.CrossRefGoogle ScholarPubMed
Nomura, S, Niki, M, Nisizawa, T, Tamaki, T & Shimizu, M (2015). Microparticles as biomarkers of blood coagulation in cancer. Biomark Cancer 7, 51–56.CrossRefGoogle ScholarPubMed
Paulus, JK & Rosenberg, AS (2016). Breast cancer and thrombosis: Timing matters. Blood 127, 793–794.CrossRefGoogle ScholarPubMed
Pierce, BL, Ballard-Barbash, R, Bernstein, L, Baumgartner, RN, Neuhouser, ML, Wener, MH, Baumgartner, KB, Gilliland, FD, Sorensen, BE & Mctiernan, A (2009). Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27, 3437.CrossRefGoogle Scholar
Pretorius, E, Swanepoel, AC, Devilliers, S & Bester, J (2017). Blood clot parameters: Thromboelastography and scanning electron microscopy in research and clinical practice. Thromb Res 154, 59–63.CrossRefGoogle ScholarPubMed
Ravishankaran, P & Karunanithi, R (2011). Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 9, 18.CrossRefGoogle ScholarPubMed
Rees, PA (2018). The Role of Extrinsic Clotting Pathway Activation in the Colorectal Cancer Microenvironment. Liverpool: University of Manchester.Google Scholar
Rose-John, S (2015). The soluble interleukin-6 receptor and related proteins. Best Pract Res Clin Endocrinol Metab 29, 787–797.CrossRefGoogle ScholarPubMed
Rose-John, S, Scheller, J, Elson, G & Jones, SA (2006). Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: Role in inflammation and cancer. J Leukocyte Biol 80, 227–236.CrossRefGoogle ScholarPubMed
Shaydakov, ME & Blebea, J (2019). Thromboelastography (TEG). StatPearls [Internet]. Liverpool: StatPearls Publishing.Google Scholar
Sueta, D, Tabata, N, Ikeda, S, Saito, Y, Ozaki, K, Sakata, K, Matsumura, T, Yamamoto-Ibusuki, M, Murakami, Y & Jodai, T (2019). Differential predictive factors for cardiovascular events in patients with or without cancer history. Medicine 98.CrossRefGoogle ScholarPubMed
Tshikudi, DM, Tripathi, MM, Hajjarian, Z, Van Cott, EM & Nadkarni, SK (2017). Optical sensing of anticoagulation status: Towards point-of-care coagulation testing. PLoS One 12, e0182491.CrossRefGoogle ScholarPubMed
Utsugi, T, Schroit, AJ, Connor, J, Bucana, CD & Fidler, IJ (1991). Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51, 3062–3066.Google ScholarPubMed
Van Der Poll, T, De Boer, JD & Levi, M (2011). The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis 24, 273–278.CrossRefGoogle Scholar
Van Rooy, M-J, Duim, W, Ehlers, R, Buys, AV & Pretorius, E (2015). Platelet hyperactivity and fibrin clot structure in transient ischemic attack individuals in the presence of metabolic syndrome: A microscopy and thromboelastography® study. Cardiovasc Diabetol 14, 86.CrossRefGoogle Scholar
Zaorsky, NG, Zhang, Y, Tchelebi, LT, Mackley, HB, Chinchilli, VM & Zacharia, BE (2019). Stroke among cancer patients. Nat Commun 10, 1–8.Google ScholarPubMed